Reported Earlier, Telix Pharmaceuticals Guides FY 2026 Revenue Of $950M-$970M, Total Income Above $1B, Reaffirms R&D Guidance Of $230M-$270M
GuidanceFY 2026 revenue and other income are expected to be in excess of US$1 billion, with revenue progressing in line with the upper end of FY 2026 guidance of US$950 million to US$970 million and US$40 million of
